We implemented this approach using a well-documented IBD model (23, –, 29), where the activity of transforming growth factor β (TGF-β) dominant-negative receptor II is driven by the CD4 promoter CD4-dnTβRII (30) (called DNR here). Here, TGFB1 is linked to inflammatory bowel disease.